A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia

Trial Profile

A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2014

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Pharmacokinetics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 21 Dec 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 01 Dec 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 27 Oct 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-001443-49).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top